Please assess the completion status of the following clinical trial:

Trial Title: Tezosentan in Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent~2. Male and female patients 18 years of age or older~3. Patients with PAH according to one of the following subgroups of the Venice Classification Group 1:~   * Idiopathic (iPAH), or~  * Familial/heritable (FPAH), or~  * Associated (APAH) with collagen vascular disease~4. Modified NYHA functional class II-III~5. Documented hemodynamic diagnosis of PAH by right heart catheterization at Baseline:~   * Resting mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg and~  * Resting mean PVR ≥ 240 dyn•s•cm-5 and~  * Pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg~Exclusion Criteria:~1. Patients with PAH in Venice Classification Groups 2-5, and PAH Group 1 subgroups not covered by inclusion criterion no. 3~2. Hypotensive patients (systemic systolic blood pressure \< 100 mmHg)~3. Patients with body weight \< 50 kg (110 lbs)~4. Patients with moderate or severe hepatic impairment (Child-Pugh B and C)~5. Patients with clinically significant chronic renal insufficiency (serum creatinine \> 2.5mg/dL / 221µmol/L)~6. Patients who have received any endothelin receptor antagonist (ERA) and/or any phosphodiesterase-5 (PDE-5) inhibitor within 28 days of Baseline~7. Patients who have received prostacyclin (epoprostenol) or prostacyclin analogs (e.g., treprostinil, iloprost) within 28 days of Baseline~8. Patients who have received any investigational drugs within 28 days of Baseline~9. Patients who have received cyclosporine A or tacrolimus within 28 days of Baseline~10. Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with the study~11. Life expectancy less than 12 months~12. Females who are lactating or pregnant or females who are not using a reliable method of birth control (failure rate less than 1% per year) during the study and for at least one month after study drug intake~13. Known hypersensitivity to any of the excipients of the drug formulation~14. Patients with positive response to vasoreactivity test

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tezosentan (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).